指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

消化系统神经内分泌肿瘤:法国跨学科临床实践指南(诊断、治疗与随访)

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
指南 / 共识 · Dig Liver Dis · 2020-03-28
一句话结论法国跨学科指南(2020年2月发布)提出消化系统神经内分泌肿瘤的诊断、治疗与随访推荐,推荐按证据等级A、B、C、D分级。

该指南由法国参与神经内分泌肿瘤管理的所有医学会共同制定,检索截至2019年5月的文献,将推荐分为A、B、C、D四个等级。指南指出神经内分泌肿瘤异质性强、诊疗复杂,诊断与预后评估依赖病理分化的分化程度、分级和分期。两类主要急症为功能性综合征和低分化癌。局限性肿瘤的治疗包括观察随访以及根据推测的侵袭性行局部或手术切除;转移性疾病治疗选择包括手术、生长抑素类似物、化疗、靶向治疗、器官驱动的局部区域治疗和肽受体放射性核素治疗。

要点

  • 诊断与预后评估需病理分析,主要依赖分化程度、分级和分期。
  • 两类主要急症为功能性综合征和低分化癌。
  • 嗜铬粒蛋白A是NET的主要生化标志物,但临床价值有限。
  • 局限性NET的治疗包括观察随访和根据推测侵袭性行局部或手术切除。
  • 转移性NET治疗选择包括手术、生长抑素类似物、化疗、靶向治疗、器官驱动局部区域治疗和肽受体放射性核素治疗。

适用人群与场景

  • 消化系统神经内分泌肿瘤(NEN)患者的管理场景。

处置流程与药物剂量

  • 局限性NET:观察随访和局部或手术切除,取决于推测的侵袭性。
  • 转移性疾病:治疗选择包括手术、生长抑素类似物、化疗、靶向治疗、器官驱动的局部区域治疗和肽受体放射性核素治疗。
  • 治疗策略目前取决于预后因素,因特异性疗效预测因素尚未确定且头对头比较未或很少进行;需考虑累积毒性和治疗对生活质量的影响,因多数NET患者生存期相对较长。

红旗征与不能漏的情况

  • 功能性综合征和低分化癌是两类主要急症。

研究设计与关键结果

  • 制定机构为法国跨学科工作组(SNFGE、GTE、RENATEN、TENPATH、FFCD、GERCOR、UNICANCER、SFCD、SFED、SFRO、SFR),方法为检索截至2019年5月的文献并将推荐分为A、B、C、D四个等级,于2020年2月发布。

证据类型、等级与局限

  • 证据类型:临床实践指南;推荐等级分为A、B、C、D四级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • 指南名称:Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up;发布机构:SNFGE、GTE、RENATEN、TENPATH、FFCD、GERCOR、UNICANCER、SFCD、SFED、SFRO、SFR;发布年份:2020年(2020年2月发布)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: This document is a summary of the French Intergroup guidelines regarding the management of digestive neuroendocrine neoplasms (NEN) published in February 2020 (www.tncd.org).

METHODS: All French medical societies involved in the management of NEN took part in this work. Recommendations were graded into four categories (A, B, C or D), according to the level of evidence found in the literature until May 2019.

RESULTS: The management of NEN is challenging because of their heterogeneity and the increasing complexity of diagnostic and therapeutic procedures. Pathological analysis is required for their diagnostic and prognostic characterization, which mainly relies on differentiation, grade and stage. The two main emergency situations are functioning syndromes and poorly-differentiated carcinoma. Chromogranin A is the main biochemical marker of NET, although of limited clinical interest. Initial characterization relies on morphological and isotopic imaging. The treatment of localized NET relies on watchful follow-up and local or surgical resection depending on its supposed aggressiveness. Treatment options for metastatic disease include surgery, somatostatin analogues, chemotherapy, targeted therapies, organ-driven locoregional therapies and peptide-receptor radionuclide therapy. As specific predictive factors of treatment efficacy are yet to be identified and head-to-head comparisons have not or only rarely been performed, the therapeutic strategy currently depends on prognostic factors. Cumulative toxicity and the impact of treatment on quality of life must be considered since survival is relatively long in most patients with NET.

CONCLUSION: These guidelines are proposed to achieve the most beneficial therapeutic strategy in clinical practice as the therapeutic landscape of NEN is becoming ever more complex. These recommendations are permanently being reviewed.

来源:Dig Liver Dis,查看原文。版权归原作者所有。

参考来源

  1. de Mestier L, Lepage C, Baudin E, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020. PMID: 32234416. doi:10.1016/j.dld.2020.02.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。